|
|||||
|
|
Characteristics of tobacco-related lung diseases in Fukuoka Prefecture,Japan: A prospective,multi-institutional,observational study |
|
| Institution: | 1. Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, Japan;2. Kirigaoka Tsuda Hospital, Fukuoka, Japan;3. Department of Respiratory Diseases, National Hospital Organization, Fukuoka Higashi Medical Center, Fukuoka, Japan;4. Department of Respiratory Medicine, Kurume General Hospital, Fukuoka, Japan;5. Division of Respiratory Medicine, Kyushu Rosai Hospital, Fukuoka, Japan;6. Department of Respiratory Medicine, Fukuoka University Chikushi Hospital, Fukuoka, Japan;7. Department of Respiratory Medicine, School of Medicine, University of Occupational and Environmental Health, Fukuoka, Japan;8. Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;9. Department of Respiratory Medicine, Wakamatsu Hospital of the University of Occupational and Environmental Health, Fukuoka, Japan;10. Division of Respirology, Neurology, and Rheumatology, Department of Medicine, Kurume University School of Medicine, Fukuoka, Japan;11. Department of Respiratory Medicine, Fukuoka University School of Medicine, Fukuoka, Japan;12. General Medical Center, Fukuoka University School of Medicine, Fukuoka, Japan;13. Medical Information Center, Kyushu University Hospital, Fukuoka, Japan;1. Chemical and Materials Engineering Department, King Abdulaziz University, P.O. Box 80204, Jeddah 21589, Kingdom of Saudi Arabia;2. Institute of Catalysis, Bulgarian Academy of Sciences, “Acad. G. Bonchev” str., block 11, Sofia 1113, Bulgaria;3. SABIC Chair of Catalysis, Chemical and Materials Engineering Department, King Abdulaziz University, P.O. Box 80204, Jeddah 21589, Kingdom of Saudi Arabia;3. From the Reagents and Assay Development Division, Discovery Sciences Department,;5. Translational Sciences Division, Cardiovascular and Metabolic Diseases Department, and;6. Structure and Biophysics Division, Discovery Sciences Department, AstraZeneca, Pepparedsleden 1, 431 83 Mölndal, Sweden and;4. the Institute of Cancer Research, Department of Medicine I, Medical University of Vienna, Borschkegasse 8a, A-1090 Vienna, Austria;1. Department of Allergy and Respiratory Medicine, The Fraternity Memorial Hospital, 2-1-11 Yokoami, Sumida-ku, Tokyo, Japan;2. Department of Laboratory Medicine, Dokkyo Medical University Saitama Medical Center, 2-1-50 Minami-koshigaya, Koshigaya-shi, Saitama, Japan;1. Janssen Korea, Ltd., 25F LS Yongsan Tower, 92 Hangang-Daero, Yongsan-Gu, Seoul, 04386, Republic of Korea;2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea;3. Division of Pulmonology, Department of Internal Medicine, Severance Hospital, Yonsei University, College of Medicine, 50-1 Yonsei-Ro, Seodaemun-Gu, Seoul, 03722, Republic of Korea;4. Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine, 164 World Cup-Ro, Yeongtong-Gu, Suwon, Gyeonggi, 16499, Republic of Korea;5. Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea |
| Abstract: | BackgroundTobacco smoking causes a variety of smoking-related diseases, death, and economic damage. Despite targeted anti-smoking campaigns, tobacco-related deaths are expected to increase in Japan. We investigated the current state of non-cancerous lung diseases such as idiopathic interstitial pneumonias (IIPs), chronic obstructive pulmonary disease (COPD), and combined pulmonary fibrosis and emphysema (CPFE), which are known to be highly related to tobacco smoking.MethodsThis prospective multi-institutional observational study involved 29 major hospitals within the Fukuoka Prefecture area (Fukuoka tobacco-related lung disease registry study group). Patients diagnosed with IIPs, including CPFE and COPD, registered from September 1, 2013 to April 30, 2016 were included. Clinical background information, laboratory and pulmonary function test results, findings of imaging tests, including chest radiography and chest computed tomography, and DNA isolated from peripheral blood were collected from each patient. Follow-up surveillance involved collection of data regarding the exacerbation of disease and death until 5 years of registration. In the present study, we report the baseline characteristics of the patients registered in this surveillance study.ResultsOverall, 1016 patients (524 with IIPs, including 145 CPFE and 492 with COPD) were enrolled. Among the patients with COPD, 96.8% were current or former smokers. Among the patients with IIPs, 69.9% were current or former smokers.ConclusionThis study revealed the current status of lung diseases potentially related to tobacco smoking in Fukuoka Prefecture. Both COPD and CPFE were highly related to tobacco smoking, whereas 30% of patients with IIPs had never smoked. |
| Keywords: | Idiopathic interstitial pneumonia Chronic obstructive pulmonary disease Combined pulmonary fibrosis and emphysema Tobacco smoking Registry study BNP"} {"#name":"keyword" "$":{"id":"kwrd0040"} "$$":[{"#name":"text" "_":"brain natriuretic peptide COPD"} {"#name":"keyword" "$":{"id":"kwrd0050"} "$$":[{"#name":"text" "_":"chronic obstructive pulmonary disease CPFE"} {"#name":"keyword" "$":{"id":"kwrd0060"} "$$":[{"#name":"text" "_":"combined pulmonary fibrosis and emphysema CT"} {"#name":"keyword" "$":{"id":"kwrd0070"} "$$":[{"#name":"text" "_":"computed tomography DNA"} {"#name":"keyword" "$":{"id":"kwrd0080"} "$$":[{"#name":"text" "_":"deoxyribonucleic acid FEV1"} {"#name":"keyword" "$":{"id":"kwrd0090"} "$$":[{"#name":"text" "_":"forced expiratory volume in 1 s FOLD"} {"#name":"keyword" "$":{"id":"kwrd0100"} "$$":[{"#name":"text" "_":"Fukuoka tobacco-related lung disease FVC"} {"#name":"keyword" "$":{"id":"kwrd0110"} "$$":[{"#name":"text" "_":"forced vital capacity HRCT"} {"#name":"keyword" "$":{"id":"kwrd0120"} "$$":[{"#name":"text" "_":"high-resolution computed tomography ICS/LABA"} {"#name":"keyword" "$":{"id":"kwrd0130"} "$$":[{"#name":"text" "_":"inhaled corticosteroid/long-acting β2 agonists IIP"} {"#name":"keyword" "$":{"id":"kwrd0140"} "$$":[{"#name":"text" "_":"idiopathic interstitial pneumonia IPF"} {"#name":"keyword" "$":{"id":"kwrd0150"} "$$":[{"#name":"text" "_":"idiopathic pulmonary fibrosis KL-6"} {"#name":"keyword" "$":{"id":"kwrd0160"} "$$":[{"#name":"text" "_":"Krebs von den Lungen-6 LAMA"} {"#name":"keyword" "$":{"id":"kwrd0170"} "$$":[{"#name":"text" "_":"long-acting muscarinic antagonists mMRC"} {"#name":"keyword" "$":{"id":"kwrd0180"} "$$":[{"#name":"text" "_":"modified medical research council NSIP"} {"#name":"keyword" "$":{"id":"kwrd0190"} "$$":[{"#name":"text" "_":"nonspecific interstitial pneumonia NT-proBNP"} {"#name":"keyword" "$":{"id":"kwrd0200"} "$$":[{"#name":"text" "_":"N-terminal pro-B-type natriuretic peptide VC"} {"#name":"keyword" "$":{"id":"kwrd0210"} "$$":[{"#name":"text" "_":"vital capacity |
| 本文献已被 ScienceDirect 等数据库收录！ | |